Benzinga | May 11, 2021 01:26PM EDT

SINTX Technologies Highlights Its FleX SN Branded Line Of Silicon Nitride-Based Products

SINTX Technologies, Inc. (www.sintx.com) (NASDAQ:SINT) ("SINTX" or the "Company"), an original equipment manufacturer of silicon nitride ceramic for medical and non-medical applications, announced today the FleX SNTM branded line of its silicon nitride based products. FleX SN reflects the company's evolution from producing monolithic spinal implants, to a wider array of silicon nitride based technologies for use in biomedical and antipathogenice applications, such as particulate silicon nitride, polymer composites, and coatings on other materials.

SINTX's FleX SN brand of silicon nitride products are created under a highly flexible R&D model, with high quality and performance, for use in many biomedical and antipathogenic applications such as wound care and dressings, spinal and dental implants, consumer facemasks, and more. Only FleX SN branded products offer the same formulation of silicon nitride that has proven its safety in over 40,000 spine fusion surgeries, and that has been rigorously tested to confirm a wide range of antiviral, antifungal and antibacterial properties.

Initial products available under the new FleX SN brand include:

* FleX SN-MC2 (Ultra-dense silicon nitride ceramic used in FDA cleared medical implants)

* FleX SN-CSC (Features a combined architecture that can mimic the cortical-cancellous structure of bone and is used in FDA cleared medical implants )

* FleX SN-PEEK (Combines the unique bioactivity of silicon nitride with the properties of conventional PEEK polymer)

* FleX SN-AP (Antipathogenic silicon nitride powder with targeted effectiveness against viruses such as SARS-CoV-2 (COVID-19), with proven mammalian cell compatibility)

The rebranding includes a redesign of the company's website, product logos, graphics, communications and correspondence. Additionally SINTX has submitted a trademark application for FleX SN which we anticipate will be awarded in the coming months.

"Since we announced our name change to SINTX Technologies in 2018, the company has been on a journey to re-invent itself," said Dr. Sonny Bal, President and CEO at SINTX Technologies. "We continue to focus on developing silicon nitride material properties, product design, and new applications in the biomedical space. Additionally, we have broadened our market focus to identify more antipathogenic and industrial applications for silicon nitride."